Skip to main content

Table 2 Adverse events (all grades) by treatment arm

From: Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI – Mel.A.) [ISRCTN75125874]

 

Number of patients (%)

 

DD/DI arm (N = 86)

HDI arm (N = 80)

Event

Grade 1

Grade 2

Grade 3

Grade 4

Grade 1

Grade 2

Grade 3

Grade 4

Flu-like symptoms

                

Fatigue

19

(22)

26

(30)

25

(29)

0

 

14

(17)

27

(34)

19

(24)

3

(4)

Fever

28

(33)

33

(38)

7

(8)

0

 

25

(31)

23

(29)

8

(10)

1

(1)

Rigors/chills

15

(17)

5

(6)

0

 

0

 

12

(15)

3

(4)

3

(4)

0

 

Arthralgia/myalgia

26

(30)

17

(20)

1

(1)

0

 

29

(36)

12

(15)

3

(4)

1

(1)

Sweating

8

(9)

3

(3)

0

 

0

 

8

(10)

1

(1)

1

(1)

0

 

Gastrointestinal

                

Nausea/vomiting

32

(37)

12

(14)

2

(2)

0

 

27

(34)

12

(15)

1

(1)

0

 

Constipation

13

(15)

5

(6)

0

 

0

 

9

(11)

3

(4)

0

 

0

 

Diarrhea

11

(13)

1

(1)

0

 

0

 

5

(6)

1

(1)

1

(1)

1

(1)

Anorexia

30

(35)

10

(12)

3

(3)

0

 

14

(17)

12

(15)

6

(7)

0

 

Hematological

                

Leukopenia

13

(15)

32

(37)

21

(24)

0

 

28

(35)

25

(31)

7

(9)

0

 

Anemia

12

(14)

0

 

1

(1)

0

 

16

(20)

3

(4)

0

 

0

 

Granulocytopenia

7

(8)

21

(24)

31

(36)

7

(8)

13

(16)

23

(29)

21

(26)

2

(2)

Platelets

11

(13)

1

(1)

3

(3)

1

(1)

16

(20)

5

(6)

0

 

0

 

Hemorrhage

2

(2)

4

(5)

0

 

0

 

1

(1)

1

(1)

0

 

0

 

Hepatic function

                

Bilirubin

3

(3)

2

(2)

0

 

0

 

6

(7)

0

 

0

 

0

 

SGOT/SGPT

16

(19)

11

(13)

18

(21)

15

(17)

21

(26)

24

(30)

18

(22)

3

(4)

Alkaline phosphatase

8

(9)

2

(2)

0

 

0

 

8

(10)

3

(4)

0

 

0

 

Liver dysfunction

0

 

2

(2)

1

(1)

0

 

3

(4)

1

(1)

1

(1)

0

 

Neurologic

                

Depression/anxiety

19

(22)

14

(16)

7

(8)

0

 

20

(25)

12

(15)

12

(15)

1

(1)

Cognitive disturbance

10

(12)

10

(12)

4

(5)

0

 

10

(12)

7

(9)

2

(2)

0

 

Cardiovascular

                

Hypertension

6

(7)

1

(1)

0

 

0

 

2

(2)

1

(1)

2

(2)

0

 

Hypotension

1

(1)

1

(1)

0

 

0

 

5

(6)

4

(5)

0

 

0

 

Ritmo

0

 

2

(2)

0

 

0

 

1

(1)

1

(1)

0

 

0

 

Cardiac dysfunction

6

(7)

4

(5)

0

 

0

 

7

(9)

6

(7)

2

(2)

1

(1)

Pulmonary

                

Dyspnea

8

(9)

3

(3)

0

 

0

 

13

(16)

4

(5)

0

 

0

 

Cough

7

(8)

1

(1)

0

 

0

 

13

(16)

1

(1)

0

 

0

 

Dermatology

                

Skin

15

(17)

7

(8)

4

(5)

0

 

15

(19)

11

(14)

2

(2)

1

(1)

Local

1

(1)

0

 

1

(1)

0

 

5

(6)

1

(1)

1

(1)

0

 

Metabolic

                

Hyperglycaemia

7

(8)

3

(3)

3

(3)

0

 

5

(6)

3

(4)

0

 

0

 

Hypoglycaemia

1

(1)

2

(2)

4

(5)

2

(2)

1

(1)

3

(4)

0

 

1

(1)